Skip to main content
Fig. 3 | Acta Neuropathologica Communications

Fig. 3

From: Clinically early-stage CSPα mutation carrier exhibits remarkable terminal stage neuronal pathology with minimal evidence of synaptic loss

Fig. 3

Microscopy of AD-ANCL patient with DNAJC5 p.L115R mutation. a An enlarged cortical pyramidal neuron with eccentric nucleus in a mutation (MC) (arrow). b A typical pyramidal neuron in a non-mutation carrier (NC) control (arrow). Stain: Hematoxylin and eosin. c An enlarged neuron contains stored lipopigment which is autofluorescent under ultraviolet light (arrow). d NC control exhibits modest neuronal accumulation of lipofuscin (arrow). e , In a MC, there is patchy reactive astrocytosis (GFAP immunohistochemistry) f Sparse reactive astrocytes in a NC control. g There is a modest increase in the number of activated microglial cells in the frontal neocortex (arrow) in comparison with a NC control (arrow) (h) (g and h, arrows indicate microglial cells) (Iba1 immunohistochemistry). a-d (scale bar in a) bar = 50 μm; (e-h) (scale bar in e) bar = 50 μm

Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us